{{chembox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 477246742
| ImageFile = Aleglitazar.svg
| ImageSize = 200px
| IUPACName = (2''S'')-2-methoxy-3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-7-benzothiophenyl]propanoic acid
| OtherNames = Ro-0728804, R-1439
|Section1={{Chembox Identifiers
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 41T4OAG59U
| IUPHAR_ligand = 7405
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 8450255
| InChI = 1/C24H23NO5S/c1-15-19(25-23(30-15)16-6-4-3-5-7-16)10-12-29-20-9-8-17(14-21(28-2)24(26)27)22-18(20)11-13-31-22/h3-9,11,13,21H,10,12,14H2,1-2H3,(H,26,27)/t21-/m0/s1
| InChIKey = DAYKLWSKQJBGCS-NRFANRHFBF
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 519504
| SMILES1 = O=C(O)[C@@H](OC)Cc4ccc(OCCc1nc(oc1C)c2ccccc2)c3c4scc3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C24H23NO5S/c1-15-19(25-23(30-15)16-6-4-3-5-7-16)10-12-29-20-9-8-17(14-21(28-2)24(26)27)22-18(20)11-13-31-22/h3-9,11,13,21H,10,12,14H2,1-2H3,(H,26,27)/t21-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = DAYKLWSKQJBGCS-NRFANRHFSA-N
| CASNo_Ref = {{cascite|changed|??}}
| CASNo=475479-34-6
| PubChem=10274777
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08845
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB08483
| SMILES=CC1=C(CCOc2ccc(C[C@H](OC)C(O[H])=O)c3c2C=CS3)N=C(c4ccccc4)O1
  }}
|Section2={{Chembox Properties
| C=24 | H=23 | N=1 | O=5 | S=1 
| Appearance=
| Density=
| MeltingPt=
| BoilingPt=
| Solubility=
  }}
|Section3={{Chembox Hazards
| MainHazards=
| FlashPt=
| AutoignitionPt =
  }}
}}

'''Aleglitazar''' is a [[peroxisome proliferator-activated receptor]] [[agonist]] (hence a [[PPAR modulator]] ) with affinity to PPARα and PPARγ, which was under development by [[Hoffmann–La Roche]] for the treatment of [[diabetes mellitus type 2|type II diabetes]].<ref name="url">{{cite web | url = http://www.ama-assn.org/ama1/pub/upload/mm/365/aleglitazar.pdf | title = Statement on a nonproprietary name adopted by the USAN Council: Aleglitazar | author = | authorlink = | coauthors = | date = | format = | work = United States Adopted Names | publisher = American Medical Association | pages = | language = | archiveurl = | archivedate = | quote = | accessdate = 2008-08-17}}</ref>  It is no longer in [[clinical_trial#Phase_III|phase III clinical trials]].<ref name="Roche halts diabetes drug trial in blow to pipeline">{{cite web | url = 
https://www.reuters.com/article/2013/07/10/us-roche-idUSBRE96903Z20130710| title = Roche halts diabetes drug trial in blow to pipeline | accessdate = 2013-07-10| author = | authorlink = | coauthors = | date = | work = | publisher = Roche | pages = | language = | archiveurl = | archivedate = | quote = }}</ref>

==References==
{{Reflist}}

{{Oral hypoglycemics}}
{{PPAR modulators}}

[[Category:Oxazoles]]
[[Category:Benzothiophenes]]
[[Category:Carboxylic acids]]
[[Category:Phenol ethers]]
[[Category:PPAR agonists]]


{{gastrointestinal-drug-stub}}